A comprehensive view of Licensing/Royalty. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Roche pays US$125M to Repare Therapeutics for global rights to develop cancer drug camonsertib RP-3500 delivered orally to treat tumors resulting from genomic alterations; deal could ultimately be worth US$1.33B
Published: June 07, 2022 by SeeNews Pharmaceuticals
Rascal + Friends announces licensing agreement with Moonbug Entertainment to launch diaper and training pants featuring CoComelon characters; products available in 10 markets including the US, UK, Ireland, Canada, Australia and New Zealand
Published: June 03, 2022 by PR Newswire
Coeptis Therapeutics receives exclusive option from University of Pittsburgh to license three chimeric antigen receptor T cell technologies that target hematologic, solid tumors; deal includes pre-clinical programs involving breast and ovarian cancer
Published: May 24, 2022 by Marketline - Deals
Emergent BioSolutions receives exclusive global rights to Chimerix’s oral brincidofovir, including Tembexa, an FDA-approved medical countermeasure for smallpox, for US$325M; Chimerix in negotiations with BARDA for Tembexa procurement contract
Published: May 20, 2022 by Marketline - Deals
Merck signs licensing deal for Sichuan Kelun Pharmaceutical’s oncology program for areas outside of China, Hong Kong, Macao, Taiwan; deal worth US$1.4B and may relate to experimental drugs SKB264 or A166 currently in Phase 2 testing in China
Published: May 20, 2022 by SeeNews Pharmaceuticals

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count